A combination of PD-1 antagonist and VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer

摘要

PROBLEM TO BE SOLVED: To provide a combination therapy for cancer treatment. A combination drug of a multi-receptor tyrosine kinase (multi-RTK) inhibitor and a programmed cell death 1 protein (PD-1) antagonist (excluding MPDL3280A) selected from a monoclonal antibody or an antigen-binding fragment thereof. The multi-RTK inhibitor is preferably a compound represented by the formula (I). (In the formula, R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is H or C1-6 alkoxy, R3 is H or halogen atom) [Selection diagram] None